Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Mallinckrodt
Baxter
McKesson
Dow

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR OLMESARTAN MEDOXOMIL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Olmesartan Medoxomil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00134160 ↗ OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed Japan Heart Foundation Phase 4 2005-08-01 The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone.
NCT00134160 ↗ OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed OSCAR Study Phase 4 2005-08-01 The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone.
NCT00139698 ↗ Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Completed Pfizer Phase 3 2005-09-01 Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
NCT00141453 ↗ ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial Completed Daiichi Sankyo Co., Ltd. Phase 3 2003-04-01 The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
NCT00151775 ↗ Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure Completed Daiichi Sankyo Inc. Phase 2/Phase 3 2005-05-01 This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Olmesartan Medoxomil

Condition Name

Condition Name for Olmesartan Medoxomil
Intervention Trials
Hypertension 31
Essential Hypertension 23
Healthy 6
Healthy Subjects 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Olmesartan Medoxomil
Intervention Trials
Hypertension 54
Essential Hypertension 27
Kidney Diseases 5
Diabetes Mellitus 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Olmesartan Medoxomil

Trials by Country

Trials by Country for Olmesartan Medoxomil
Location Trials
United States 367
Germany 29
Netherlands 13
Mexico 11
Poland 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Olmesartan Medoxomil
Location Trials
California 17
Florida 16
Texas 15
Ohio 15
North Carolina 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Olmesartan Medoxomil

Clinical Trial Phase

Clinical Trial Phase for Olmesartan Medoxomil
Clinical Trial Phase Trials
Phase 4 24
Phase 3 37
Phase 2/Phase 3 1
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Olmesartan Medoxomil
Clinical Trial Phase Trials
Completed 67
Unknown status 7
Terminated 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Olmesartan Medoxomil

Sponsor Name

Sponsor Name for Olmesartan Medoxomil
Sponsor Trials
Daiichi Sankyo, Inc. 23
Daiichi Sankyo Inc. 23
Daiichi Sankyo Europe, GmbH 9
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Olmesartan Medoxomil
Sponsor Trials
Industry 111
Other 16
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Mallinckrodt
Medtronic
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.